Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies: Which Stock Should You Track
- October 21, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Fredun Pharmaceuticals PE 57.90, mkt cap Rs 2,537 crore. Orchid Pharma PE 548.30, mkt cap Rs 5,877 crore. Venus Remedies PE 19.28, mkt cap Rs 2,240 crore.
Quick Answer
Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Fredun Pharmaceuticals carries a market capitalisation of about Rs 2,537 crore, against Rs 5,877 crore for Orchid Pharma and Rs 2,240 crore for Venus Remedies, with return on equity of 11.73%, 1.34% and 15.49% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies: Company Overview
Fredun Pharmaceuticals is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,537 crore, a return on equity of 11.73% and a book value of Rs 162.78 per share. Its quarterly revenue moved from Rs 119.85 crore in June 2025 to Rs 228.25 crore in June 2026, a change of +90.4%.
Orchid Pharma is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 5,877 crore, a return on equity of 1.34% and a book value of Rs 261.22 per share. Its quarterly revenue moved from Rs 274.76 crore in June 2025 to Rs 306.00 crore in June 2026, a change of +11.4%.
Venus Remedies is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,240 crore, a return on equity of 15.49% and a book value of Rs 496.56 per share. Its quarterly revenue moved from Rs 140.59 crore in June 2025 to Rs 181.48 crore in June 2026, a change of +29.1%.
Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies: Valuation and Profitability Snapshot
| Metric | Fredun Pharmaceuticals | Orchid Pharma | Venus Remedies |
|---|---|---|---|
| Market Cap (approx.) | Rs 2,537 crore | Rs 5,877 crore | Rs 2,240 crore |
| PE Ratio (TTM) | 57.90 | 548.30 | 19.28 |
| PB Ratio | 9.43 | 3.76 | 3.38 |
| Return on Equity (ROE) | 11.73% | 1.34% | 15.49% |
| EPS (TTM, Rs) | 26.50 | 1.79 | 86.92 |
| Dividend Yield | 0.02% | 0.00% | 0.60% |
| Debt to Equity | 0.80 | 0.28 | 0.02 |
| Book Value per Share (Rs) | 162.78 | 261.22 | 496.56 |
Check the Univest Screener for Live Data
On valuation, Fredun Pharmaceuticals trades at a PE of 57.90 and a PB of 9.43, Orchid Pharma at a PE of 548.30 and a PB of 3.76, while Venus Remedies trades at a PE of 19.28 and a PB of 3.38. On return on equity, the three post 11.73%, 1.34% and 15.49% respectively, and on dividend yield they stand at 0.02%, 0.00% and 0.60%. Orchid Pharma has the highest market capitalisation of the three at Rs 5,877 crore, while Venus Remedies has the lowest at Rs 2,240 crore. Orchid Pharma has the highest PE ratio of the three at 548.30, while Venus Remedies has the lowest at 19.28. Venus Remedies has the highest return on equity of the three at 15.49%, while Orchid Pharma has the lowest at 1.34%. Fredun Pharmaceuticals has the highest debt to equity ratio of the three at 0.80, while Venus Remedies has the lowest at 0.02. Debt to equity is 0.80, 0.28 and 0.02 for the three respectively.
Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| Fredun Pharmaceuticals | Rs 228.25 crore | Rs 13.13 crore | +90.4% | +7.1% | +93.9% |
| Orchid Pharma | Rs 306.00 crore | Rs 2.58 crore | +11.4% | -18.6% | NA |
| Venus Remedies | Rs 181.48 crore | Rs 22.97 crore | +29.1% | -31.3% | +139.3% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | Fredun Pharmaceuticals | Orchid Pharma | Venus Remedies |
|---|---|---|---|
| June 2025 | Rs 119.85 crore | Rs 274.76 crore | Rs 140.59 crore |
| September 2025 | Rs 145.30 crore | Rs 204.29 crore | Rs 194.46 crore |
| December 2025 | Rs 160.93 crore | Rs 212.88 crore | Rs 182.78 crore |
| March 2026 | Rs 213.05 crore | Rs 376.10 crore | Rs 264.35 crore |
| June 2026 | Rs 228.25 crore | Rs 306.00 crore | Rs 181.48 crore |
Quarterly net profit (Rs crore)
| Quarter | Fredun Pharmaceuticals | Orchid Pharma | Venus Remedies |
|---|---|---|---|
| June 2025 | Rs 6.77 crore | -Rs 6.89 crore | Rs 9.60 crore |
| September 2025 | Rs 9.43 crore | -Rs 3.33 crore | Rs 20.13 crore |
| December 2025 | Rs 10.48 crore | -Rs 12.15 crore | Rs 25.58 crore |
| March 2026 | Rs 10.78 crore | Rs 24.84 crore | Rs 47.50 crore |
| June 2026 | Rs 13.13 crore | Rs 2.58 crore | Rs 22.97 crore |
Fredun Pharmaceuticals reported revenue of Rs 119.85 crore in June 2025 and Rs 228.25 crore in June 2026, a change of +90.4% across the period. Its highest quarterly revenue in this window was Rs 228.25 crore in June 2026. Net profit stood at Rs 13.13 crore in June 2026, which is a net profit margin of 5.75%.
Orchid Pharma reported revenue of Rs 274.76 crore in June 2025 and Rs 306.00 crore in June 2026, a change of +11.4% across the period. Its highest quarterly revenue in this window was Rs 376.10 crore in March 2026. Net profit stood at Rs 2.58 crore in June 2026, which is a net profit margin of 0.84%. Orchid Pharma reported a net loss in June 2025, September 2025 and December 2025.
Venus Remedies reported revenue of Rs 140.59 crore in June 2025 and Rs 181.48 crore in June 2026, a change of +29.1% across the period. Its highest quarterly revenue in this window was Rs 264.35 crore in March 2026. Net profit stood at Rs 22.97 crore in June 2026, which is a net profit margin of 12.66%.
Download the Univest iOS App or Univest Android App to track Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and the gap between reported profit and cash generation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies
What is the market cap difference between Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies?
Ans. As of October 2026, Fredun Pharmaceuticals has a market cap of approximately Rs 2,537 crore, Orchid Pharma is at approximately Rs 5,877 crore, and Venus Remedies is at approximately Rs 2,240 crore. Orchid Pharma is the largest of the three, and its market capitalisation is about 2.6 times that of Venus Remedies, the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies comparison.
What are the PE and PB ratios of Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies?
Ans. As of October 2026, the PE ratios stand at 57.90, 548.30 and 19.28 respectively, and the price to book ratios stand at 9.43, 3.76 and 3.38 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and healthcare and against each company’s own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.
Which of the three has the highest ROE?
Ans. Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies post ROE of 11.73%, 1.34% and 15.49% respectively as of October 2026. Venus Remedies has the highest return on equity of the three at 15.49%, while Orchid Pharma has the lowest at 1.34%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies figures.
Which of these three stocks pays the highest dividend yield?
Ans. Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies carry dividend yields of 0.02%, 0.00% and 0.60% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.
What is the debt to equity ratio for Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies?
Ans. Fredun Pharmaceuticals carries a debt to equity of 0.80, Orchid Pharma of 0.28, and Venus Remedies of 0.02. Fredun Pharmaceuticals has the highest debt to equity ratio of the three at 0.80, while Venus Remedies has the lowest at 0.02. The debt to equity ratio compares total borrowings with shareholders’ funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and healthcare need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies comparison.
What were the latest quarterly revenue and net profit of Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies?
Ans. For Q1 FY27 (quarter ended June 2026), Fredun Pharmaceuticals reported revenue of Rs 228.25 crore and net profit of Rs 13.13 crore, Orchid Pharma reported revenue of Rs 306.00 crore and net profit of Rs 2.58 crore, and Venus Remedies reported revenue of Rs 181.48 crore and net profit of Rs 22.97 crore. Compared with the quarter ended June 2025, revenue changed by +90.4% for Fredun Pharmaceuticals, +11.4% for Orchid Pharma and +29.1% for Venus Remedies. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies results.
Does this comparison recommend one of Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and healthcare, it also helps to look at factors such as regulatory approvals, export orders, raw material costs and the gap between reported profit and cash generation. Reading the latest filings and investor presentations of Fredun Pharmaceuticals, Orchid Pharma and Venus Remedies directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in Fredun Pharmaceuticals vs Orchid Pharma vs Venus Remedies.
